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A
 
BSTRACT
Objectives:
 
Asthmatics are considered to be at high
risk for pulmonary complications during general anes-
thesia with tracheal intubation. The purpose of the
present study was to determine the usefulness of peri-
operative corticosteroids for mild asthmatics in pre-
venting perioperative exacerbation of asthma.
 
Methods:
 
Airway hyperresponsiveness to inhaled metha-
choline was determined in patients with intermittent
(
 
n
 
 = 27) and mild persistent (
 
n
 
 = 48) asthma before
general anesthesia who underwent surgery between
January 1990 and January 1999. All patients were
treated with corticosteroids during the perioperative
period, consisting of a course of oral prednisolone
10–20 mg/day for 1–2 days pre-operatively, methyl-
prednisolone 80–125 mg 2 h before the operation,
followed by 80 mg methylprednisolone just after the
operation. The incidence of perioperative broncho-
spasm was evaluated based on medical records.
Airway hyperresponsiveness to inhaled methacholine
was determined in six other asthmatics before and
after a similar regimen of perioperative corticosteroids
treatment.
 
Results:
 
Only three cases (4.0%) developed mild
asthma during the perioperative period. No evidence
of adverse effects of corticosteroids was noted in any
case. The use of the same therapeutic regimen in
another six asthmatics significantly suppressed airway
hyperresponsiveness to inhaled methacholine.
 
Conclusions:
 
Our results suggest that perioperative
corticosteroids are effective in preventing perioperative
bronchospasm in stable asthmatics during surgery under
general anesthesia by suppressing airway hyper-
responsiveness.
 
Key words:
 
airway hyperresponsiveness, bronchial
asthma, general anesthesia, perioperative broncho-
spasm.
 
I
 
NTRODUCTION
 
Patients with asthma show airway hyperresponsiveness
(AHR) to various stimuli, airway obstruction and mucus
hypersecretion and, thus, are thought to be at high risk
for pulmonary complications during general anesthesia
with tracheal intubation.
 
1
 
 The recent increase in the
prevalence of asthma
 
2,3
 
 suggests that the number of asth-
matics undergoing surgery will also increase in the
future. Pulmonary function is one of the most important
determinants of prognosis in asthmatics undergoing
surgery, especially chest surgery.
 
4,5
 
 Even when the pre-
operative lung function is normal, severe lung dysfunc-
tion could develop in asthmatics due to various stimuli
and medications administered throughout perioperative
procedures. Several investigators have reported that the
incidence of pulmonary complications is higher in patients
with asthma than in those without asthma.
 
6,7
 
 Surgery
should be performed in patients with active asthma
following thorough treatment including corticosteroids
(CSs), with the exception of emergency cases. While the
importance of perioperative CSs for mild asymptomatic
asthmatics is controversial,
 
8–10
 
 the perioperative treat-
ment protocol for mild and stable asthmatics with
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previous attacks or for patients with AHR but without any
history of asthma attacks is yet to be established.
Bronchial asthma is a chronic airway inflammatory
disease, characterized by cellular infiltration into the air-
ways, including mast cells, B cells, T cells and eosino-
phils. Airway hyperresponsiveness in asthma is linked to
chronic allergic inflammation of the airway.
 
11,12
 
 Cortico-
steroids are one of the most effective therapeutic agents
for asthma. Although the precise mode of action is still
unknown, it is likely that CSs suppress allergic inflam-
mation of the airway and result in the suppression of
AHR.
 
13,14
 
 We hypothesized that perioperative CSs could
suppress AHR in asthmatics and prevent operation-
induced bronchospasm. Thus, we treated mild asympto-
matic asthmatics who required general anesthesia with
perioperative CSs. The present study demonstrates the
outcome of perioperative CSs for stable asthmatics and
the effects of CSs on AHR.
 
M
 
ETHODS
 
Patients
 
Between January 1990 and January 1999, 75 adult
asthmatics were referred by the surgical services to the
out-patient clinic of the Second Department of Internal
Medicine, Nagasaki University School of Medicine,
Nagasaki, Japan, before surgery requiring general
anesthesia and tracheal intubation. Bronchial asthma
was diagnosed and its severity was defined based on the
 
Expert Panel Report 2, Guidelines for the Diagnosis and
Management of Asthma
 
.
 
15
 
 Most patients were new refer-
rals previously treated by general practitioners, while a
few were treated by the out-patient clinic of the Second
Department of Internal Medicine, Nagasaki University
School of Medicine. Atopy was defined when one or
more skin prick tests and/or serum allergen-specific IgE
(RAST) to 10 common aeroallergens were positive. This
study was approved by the Ethics Review Committee of
Nagasaki University and written informed consent was
obtained from each subject.
 
Pulmonary function and methacholine 
inhalation tests
 
Spirometry and methacholine (MCh) inhalation test were
performed on the same day within 2 weeks prior to the
operation. All medications were stopped 24 h before
the tests and the absence of wheeze was confirmed
clinically by chest auscultation. Spirometry was performed
with the patient seated, using an electronic spirometer
(DISCOM-21FX; Chest, Tokyo, Japan). The MCh inha-
lation test was performed as reported previously.
 
16
 
 In
brief, MCh aerosol was administered from a hand-held
DeVilbiss nebulizer (no. 565ON; DeVilbiss, Somerset,
PA, USA) during tidal breathing for 2 min. The operating
airflow rate was 5 L/min. Isotonic saline was inhaled first
as a control. This was followed by doubling concentra-
tions of MCh from 0.049 to 25 mg/mL. The forced
expiratory volume in one second (FEV
 
1.0
 
) was measured
after each inhalation with a spirometer (DISCOM-21FX;
Chest MI, Tokyo, Japan). The fall in FEV
 
1.0
 
% was
calculated relative to the post-saline FEV
 
1.0
 
. The test
was continued until FEV
 
1.0
 
 had fallen > 20% or until the
maximal concentration of MCh had been administered.
Airway hyperresponsiveness was expressed as the cumu-
lative dose of MCh that would provoke a fall in FEV
 
1.0
 
 of
20% (PD
 
20
 
). At the end of the test, any fall in FEV
 
1.0
 
 was
reversed with inhalation of salbutamol.
 
Protocol
 
Subjects were treated as follows: oral prednisolone
10–20 mg/day for 1–2 days pre-operatively, methyl-
prednisolone 80–125 mg 2 h before the operation and
80 mg methylprednisolone just after the operation. Enrol-
ment in the present study allowed the subjects to remain
on the same medications for asthma. Retrospectively,
the incidence of bronchospasm during the perioperative
period to 2 weeks after the operation was evaluated
from medical records and questionnaires. The incidence
of adverse effects of CSs, including signs of wound
infection, delay or difficulty in wound healing or wound
dehiscence were also evaluated.
During the study period, three asthmatics who were
not treated with perioperative CSs developed broncho-
spasm and the clinical backgrounds of these patients
were analyzed from the medical records.
 
Effects of short-term CSs on AHR
 
Airway hyperresponsiveness to inhaled methacholine
was determined in a different group of six adult asth-
matics, who were not to undergo operation, before and
after a similar CSs treatment regimen used in the
operation group as described above.
 PERIOPERATIVE CORTICOSTEROIDS FOR ASTHMA 187
 
Data analysis
 
Data are expressed as the mean 
 
±
 
 SD. The PD
 
20
 
 was
compared before and after GCs treatment, using the
Wilcoxon rank sum test after conversion into logarithmic
values because of the high variance.
 
R
 
ESULTS
 
Patient characteristics
 
Patient characteristics are shown in Table 1. All were
defined as having intermittent or mild persistent asthma.
In most patients, medication consisted of inhaled 
 
β
 
2
 
-
adrenergic receptor agonists on demand only, while a
small proportion of patients used only beclomethasone
dipropionate inhaler (BDI). Because most patients had
been treated previously by general practitioners and
were seen perioperatively only in our out-patients clinic,
the medications prescribed for the subjects seem to
be suboptimal. The most frequent surgical area in
the present study was the abdomen, followed by the
chest. Pulmonary function was normal in all subjects
(mean vital capacity 101 
 
±
 
 16% predicted; mean
FEV
 
1.0
 
 88 
 
±
 
 15% predicted) and MCh inhalation tests
demonstrated the presence of AHR in all subjects (mean
PD
 
20
 
 1.34 
 
±
 
 1.44 mg/mL).
 
Outcome of pre-operative CSs treatment
 
Only three cases (4.0%) developed mild asthma post-
operatively and all patients were successfully treated with
salbutamol sulfate inhalation. No evidence of adverse
effects of CSs was found in any case.
 
Three asthmatics without pre-operative CSs 
treatment
 
Three patients with mild asthma underwent surgery
without pre-operative consultation for their asthma by a
pulmonary physician. Surgery was performed in these
patients without CSs treatment. Table 2 demonstrates
the background and episodes of asthma in these three
cases. Cases 1 and 2 were categorized as non-atopic,
mild persistent asthma and well controlled 1 week prior
to the operation by inhaled 
 
β
 
2
 
-adrenergic receptor
agonist on demand only. Case 3 was atopic without any
history of asthma. She was not on any medication and
had normal pulmonary function tests. Anesthesia was
induced in all cases by fentanyl and cases 1 and 2 were
maintained by nitrous oxide and isoflurane (nitrous
oxide–oxygen–isoflurane (GOI)). Case 1 developed a
severe asthma attack 18 h after the operation. Case 2
developed bronchospasm at the time of extubation and
subsequently became poorly controlled. The operation
for case 3 was cancelled because of severe broncho-
spasm at intubation. Subsequently, case 3 presented
with typical asthma attacks. These episodes were
treated with CSs and all cases were well controlled by
BDI. At the second skin grafting for case 2 and at
reoperation for case 3, these patients received perioper-
ative CSs and neither developed pulmonary complica-
tions. Clinically, allergy to drugs or latex was not
identified in these three patients.
 
Effects of short-term CSs on AHR
 
Airway hyperresponsiveness was determined before and
after a similar CSs treatment in another group of six
adult asthmatics (male : female ratio 4 : 2; mean age
46.3 
 
±
 
 9.8 years; atopic : non-atopic ratio 3 : 3). The
same dose of CSs for perioperative treatment sig-
nificantly (
 
P
 
 < 0.05) reduced AHR to inhaled MCh
(1.48 
 
±
 
 1.36 
 
vs
 
 8.42 
 
±
 
 9.65 mg/mL before and after
CSs, respectively; Fig. 1).
 
Table 1
 
Patient characteristics
Sex (M/F) 50/25
Age (years)
Mean 51.5 
 
± 
 
18.4
Range 16–77
Type of asthma
Atopic 29
Non-atopic 36
Unknown 10
Severity of asthma
Intermittent 27
Mild persistent 48
Moderate persistent 0
Severe persistent 0
Therapy
None 24
Inhaled 
 
β
 
2
 
-adrenergic receptor agonist 44
BDI 7
Oral PSL 0
Operation time (h)
Mean 4.3 
 
± 
 
1.9
Range 1.8–8.4
Chest 20
Abdomen 27
Head and neck 13
Limbs 15
 
Where appropriate, data are the mean 
 
± 
 
SD of 75 subjects.
BDI, beclomethasone dipropionate inhalation; PSL, predonisolone.
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D
 
ISCUSSION
 
A key finding of the present study is that perioperative
CSs are effective in preventing perioperative broncho-
spasm in steroid-independent mild asthmatics during
surgery under general anesthesia. Patients with asthma
undergoing surgery requiring general anesthesia are clas-
sified into one of the following categories:
 
17
 
 (i) patients
in continuous asymptomatic periods without any medi-
cation; (ii) patients with unstable asthma; and (iii) patients
in transient asymptomatic periods with anti-asthma
medications. It is necessary for asthmatics classified as
category (ii) or (iii) to be adequately treated before
operation, including the use of CSs, excluding, of
course, emergency cases. At this stage, however, it is
uncertain whether pre-operative anti-asthma treatment
is necessary for patients in category (i). The 
 
Expert Panel
Report 2, Guidelines for the Diagnosis and Management
of Asthma
 
15
 
 recommends CSs treatment for patients
showing perioperative pulmonary dysfunction and CSs
dependence. In the present study, we treated asthmatics
undergoing surgery with CSs even for patients in the
intermittent or mild persistent categories who had normal
pulmonary function tests and showed no evidence of
CSs dependence. Case 3 in the present study, who
developed bronchospasm during intubation and was not
treated with CSs pre-operatively, had no history of
asthma, but had AHR. In this regard, we have recently
reported that AHR persists in adult subjects outgrowing
childhood asthma,
 
16
 
 suggesting that it is better to sup-
press AHR by CSs in asymptomatic asthma to prevent
pulmonary complications during perioperative periods.
Although a double-blind study design is preferable in
order to prove the usefulness of perioperative CSs treat-
ment for the prevention of asthma attacks, it was ethically
impossible to do so in the present study. Instead, we
included in the present study three cases who developed
 
Table 2
 
Three cases who were not treated with steroids pre-operatively
Case 1 Case 2 Case 3
Age (years)/Sex 65/M 68/M 32/F
Asthma duration (years) 7 Unknown 0
Type of asthma Non-atopic Non-atopic Atopic
Severity of asthma Mild persistent Mild persistent –
Therapy before operation T, 
 
β
 
T None
VC (% predicted) 102.2 ND 90.0
FEV
 
1.0
 
/FVC (%) 88.3 ND 92.3
PD
 
20
 
 (mg/dL) 0.15 ND 2.06
Surgery diagnosis Esophageal cancer Systemic burn PDA
Procedures Esophagectomy Skin grafting –*
Duration (h : min) 04 : 05 04 : 45 –*
Induction Fentanyl Fentanyl Fentanyl
Maintenance GOI GOI –*
Episodes Severe attack at 18 h postop. Bronchospasm at extubation Bronchospasm at intubation
 
*The operation was cancelled due to intubation-induced bronchospasm.
T, sustained release theophiline; 
 
β
 
, inhaled 
 
β
 
2
 
-adrenergic receptor agonist as needed for symptoms; GOI, nitrous oxide and isoflorane; PDA, 
patent ductus arteriosus; ND; not done; VC, vital capacity; FEV
 
1.0
 
, forced expiratory volume in 1 s; FVC, forced vital capacity.
 
Fig. 1
 
Airway hyperresponsiveness to inhaled methacholine
before and after corticosteroid treatment in six asthmatics.
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asthma without perioperative CSs treatment. All anes-
thetic reagents known to induce histamine release,
bronchoconstriction or cholinergic nerve stimulation are
contraindicated for asthmatics (e.g. thiopental and tubo-
curarine).
 
7,18
 
 The three cases who did not receive peri-
operative CSs treatment were maintained by fentanyl, a
narcotic agent, and developed asthma attacks. Because
fentanyl was used in other asthmatics during the same
study period in our hospital and is generally preferred for
asthmatics, it is unlikely that fentanyl induced the asthma
attacks in these three subjects. Anesthesia was main-
tained in cases 1 and 2 by isoflurane. Isoflurane induces
broncodilatation similar to halothane and is often used
for asthmatics.
 
19
 
 Although rare, isoflurane also induces
bronchoconstriction in some patients.
 
20
 
 However, it is
unlikely that isoflurane caused bronchoconstriction in
these two cases because they developed asthma attacks
after surgery. Various stimuli during operation, including
intubation and extubation, may have caused bronchos-
pasm in these three subjects with AHR, irrespective of the
anesthetic reagent used.
The 
 
Expert Panel Report 2, Guidelines for the Diagnosis
and Management of Asthma
 
 recommendations for the
treatment of mild persistent asthma are either inhaled
CSs or cromolyn,
 
15
 
 whereas only seven of 48 patients
used inhaled CSs in the present study, suggesting sub-
optimal treatment. Because long-term use of inhaled
CSs suppresses AHR,
 
21
 
 optimal treatment with inhaled
CSs in the weeks prior to surgery may have been ade-
quate to prevent perioperative complications without
having to administer systemic CSs. To date, it is uncertain
whether short-term oral and/or intravenous CSs can
inhibit AHR.
 
22,23
 
 Thus, AHR was determined in a different
set of asthmatics before and after CSs similar to the pre-
operative CSs treatment. Our results indicate that short-
term oral and intravenous CSs significantly inhibit AHR.
Compared with inhaled CSs, our protocol with oral and
intravenous CSs requires a shorter treatment period
and has a clear advantage regarding compliance with
therapy. The doses of CSs used in the present study were
based on the regular dose for acute asthma. Thus, a
comparative study using different doses of CSs will be
planed as our next study to determine the adequate CSs
doses for use in intermittent and mild persistent asth-
matics during surgery.
Although the present study was not performed in a
double-blinded fashion, as mentioned above, neither
severe attacks nor CSs-induced adverse effects
 
24
 
 occur-
red. We conclude that pre-operative CSs treatment for
asthmatics, even for patients in the intermittent or mild
persistent categories, is advisable to prevent operation-
induced asthma attacks by, at least partly, inhibiting AHR.
 
R
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